[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO973459L - Vismut-forbindelser - Google Patents

Vismut-forbindelser

Info

Publication number
NO973459L
NO973459L NO973459A NO973459A NO973459L NO 973459 L NO973459 L NO 973459L NO 973459 A NO973459 A NO 973459A NO 973459 A NO973459 A NO 973459A NO 973459 L NO973459 L NO 973459L
Authority
NO
Norway
Prior art keywords
bismuth compounds
bismuth
compounds
contrast
agents
Prior art date
Application number
NO973459A
Other languages
English (en)
Other versions
NO973459D0 (no
Inventor
Jo Klaveness
Arne Berg
Torsten Almen
Klaes Golman
Michael Droege
Shi-Bao Yu
Original Assignee
Nycomed Imaging As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9501560.8A external-priority patent/GB9501560D0/en
Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As
Publication of NO973459D0 publication Critical patent/NO973459D0/no
Publication of NO973459L publication Critical patent/NO973459L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/94—Bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Anvendelse av kontrastmidler inneholdende vismul-clustere og/eller organiske vismut-forbindelser og kontrastmedia inneholdende slike vismut- forbindelser i diagnostisk avbildning, spesielt røntgen, MRI, ultralyd og srintigrafi. Vismut-forbindelsene er også nyttige for terapi, spesielt som antimikrobielle midler og antiulcer-midler. Nye vismut-forbindelser er også beskrevet.
NO973459A 1995-01-26 1997-07-25 Vismut-forbindelser NO973459L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9501560.8A GB9501560D0 (en) 1995-01-26 1995-01-26 Contrast agents
US08/486,225 US5817289A (en) 1995-01-26 1995-06-07 Non-cluster type bismuth compounds
PCT/GB1996/000183 WO1996022994A1 (en) 1995-01-26 1996-01-26 Bismuth compounds

Publications (2)

Publication Number Publication Date
NO973459D0 NO973459D0 (no) 1997-07-25
NO973459L true NO973459L (no) 1997-09-25

Family

ID=26306382

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973459A NO973459L (no) 1995-01-26 1997-07-25 Vismut-forbindelser

Country Status (11)

Country Link
US (1) US6117412A (no)
EP (1) EP0805815B1 (no)
JP (1) JPH10512877A (no)
CN (1) CN1177357A (no)
AU (1) AU4493796A (no)
CA (1) CA2211873A1 (no)
DE (1) DE69620582T2 (no)
FI (1) FI973117A (no)
HU (1) HUP9900428A2 (no)
NO (1) NO973459L (no)
WO (1) WO1996022994A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501560D0 (en) * 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
DE19635419C1 (de) * 1996-08-23 1998-08-20 Schering Ag Wismutdendrimere und ihre Verwendung als Röntgenkontrastmittel
KR100721365B1 (ko) * 2003-04-08 2007-05-23 토소가부시키가이샤 신규 비스무트 화합물, 그 제조방법 및 막의 제조방법
AU2003263580A1 (en) * 2003-08-12 2005-02-25 Biocon Limited Mycophenolic acid bismuth salt
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
CN1986554B (zh) * 2005-12-20 2010-08-11 上海化学试剂研究所 三(4-乙氧基苯基)铋的制备方法
EP2348052A3 (en) 2007-09-17 2011-10-26 The Regents of The University of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
US20110064674A1 (en) * 2008-05-21 2011-03-17 Carnegie Mellon University Luminescent multimodal nanoparticle probe system and method of manufacture thereof
AU2012229156A1 (en) 2011-03-11 2013-10-31 Board Of Regents Of The University Of Nebraska Biomarker for coronary artery disease
CN103771456A (zh) * 2012-10-26 2014-05-07 吴学文 一种铁氰化铋化合物及其纳米ct造影剂的制备方法
JP6460937B2 (ja) * 2014-12-04 2019-01-30 信越化学工業株式会社 末端にアミノ基を有するポリアルキレングリコール誘導体の製造方法
US10377775B2 (en) 2014-12-04 2019-08-13 Shin-Etsu Chemical Co., Ltd. Method for producing polyalkylene glycol derivative having amino group at end
US9708350B2 (en) 2014-12-04 2017-07-18 Shin-Etsu Chemical Co., Ltd. Method for producing polyalkylene glycol derivative having amino group at end, polymerization initiator for use in the same, and alcohol compound as raw material for the polymerization initiator
FI3383920T3 (fi) 2015-11-30 2024-04-10 Univ California Kasvainspesifinen hyötyaineen antaminen ja immuuniaktivointi käyttämällä erittäin spesifiseen kasvainsolun pinta-antigeeniin kohdentuvaa ihmisen vasta-ainetta
EP3538551A4 (en) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF
WO2019177084A1 (ja) 2018-03-16 2019-09-19 株式会社トクヤマ ビスマス化合物、硬化性組成物、および硬化体
EP4183579A4 (en) 2020-07-17 2024-09-11 Tokuyama Corp CURABLE COMPOSITION AND CURRED BODY THEREOF
IL300528A (en) 2020-08-07 2023-04-01 Fortis Therapeutics Inc Immune conjugates targeting cd46 and methods of using them

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1003685A (en) * 1961-06-29 1965-09-08 American Cyanamid Co Improvements in or relating to germicidal finishes
US3239411A (en) * 1962-06-14 1966-03-08 M & T Chemicals Inc Organo bismuth biocide
US3247050A (en) * 1962-10-11 1966-04-19 M & T Chemicals Inc Organo bismuth biocide
US3466366A (en) * 1963-05-15 1969-09-09 M & T Chemicals Inc Method of controlling bacteria with an organobismuth ethylenic carboxylate and polymer thereof
US4153685A (en) * 1968-11-23 1979-05-08 Schering Corporation Bismuth complex preparations
US3753990A (en) * 1972-01-17 1973-08-21 Procter & Gamble Phenylbismuth bis(2-pyridinethiol 1-oxide)
BE809388A (en) * 1974-01-04 1974-05-02 Bismuthyl prostanoate derivs for ulcer control - in digestive system and prepd from prostanoic acid with bismuth oxide, hydroxide or salt
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4652519A (en) * 1983-02-03 1987-03-24 Yeda Research And Development Company Limited Bifunctional chelating agents and process for their production
US4588589A (en) * 1983-10-13 1986-05-13 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
US4687659A (en) * 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US4826673A (en) * 1985-01-09 1989-05-02 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
CA1282069C (en) * 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
IT1213029B (it) * 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
JPS63225381A (ja) * 1986-08-29 1988-09-20 Nippon Zeon Co Ltd 肝疾患治療剤
US5482700A (en) * 1987-03-31 1996-01-09 Schering Aktiengesellschaft Substituted polyamino, polycarboxy complexing agent dimers for MRI and X-ray contrast
WO1989000557A1 (en) * 1987-07-16 1989-01-26 Cockbain, Julian, Roderick, Michaelson Aminopolycarboxylic acids and derivatives thereof
US5196205A (en) * 1987-10-12 1993-03-23 Borody Thomas J Method for treatment of gastro intestinal disorders
CH679582A5 (no) * 1988-07-18 1992-03-13 Glaxo Group Ltd
AU641903B2 (en) * 1988-10-26 1993-10-07 Glaxo Group Limited Carboxylic acid derivatives
US5013560A (en) * 1989-03-17 1991-05-07 The Procter & Gamble Company Microbially-stable bismuth-containing liquid pharmaceutical suspensions
WO1991003241A1 (de) * 1989-09-07 1991-03-21 Gerhard Gergely Magensäure bindende, pharmazeutische zubereitung
YU45590A (sh) * 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
WO1992017215A1 (en) * 1990-03-28 1992-10-15 Nycomed Salutar, Inc. Contrast media
GB9009437D0 (en) * 1990-04-26 1990-06-20 Glaxo Group Ltd Chemical compounds
ES2084174T3 (es) * 1990-07-20 1996-05-01 Tillotts Pharma Ag Productos y procesos para el tratamiento del conducto alimentario.
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
CA2052698A1 (en) * 1990-10-11 1992-04-12 Roger G. Berlin Treatment of peptic ulcer
WO1993002713A1 (en) * 1991-08-05 1993-02-18 Mallinckrodt Medical, Inc. Heavy metal clusters for use as imaging agents
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
ES2130152T3 (es) * 1991-12-06 1999-07-01 Glaxo Group Ltd Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
JP3668983B2 (ja) * 1993-08-23 2005-07-06 日産化学工業株式会社 トリス（置換フェニル）ビスマス誘導体
US5482669A (en) * 1994-05-23 1996-01-09 General Motors Corporation Pulsating gas-assisted injection molding method and apparatus
US5672335A (en) * 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
HUT77553A (hu) * 1994-11-30 1998-05-28 Schering Aktiengesellschaft Eljárás fémeket tartalmazó kelát komplexek alkalmazására a máj és az epe röntgendiagnosztikájában
GB9501560D0 (en) * 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents

Also Published As

Publication number Publication date
MX9705609A (es) 1997-10-31
DE69620582T2 (de) 2002-11-07
FI973117A (fi) 1997-09-25
FI973117A0 (fi) 1997-07-25
AU4493796A (en) 1996-08-14
CA2211873A1 (en) 1996-08-01
CN1177357A (zh) 1998-03-25
EP0805815B1 (en) 2002-04-10
HUP9900428A2 (hu) 1999-06-28
JPH10512877A (ja) 1998-12-08
NO973459D0 (no) 1997-07-25
EP0805815A1 (en) 1997-11-12
US6117412A (en) 2000-09-12
WO1996022994A1 (en) 1996-08-01
DE69620582D1 (de) 2002-05-16

Similar Documents

Publication Publication Date Title
NO973459L (no) Vismut-forbindelser
CL2004001126A1 (es) Complejos de polimeros en cascada y sus composiciones farmaceuticas, utiles para la preparacion de agentes de diagnostico por nmr.
NO910711D0 (no) Middel bestaaende av cavitat- eller clathrat- dannende vert/gjest-komplekser som kontrastmiddel.
NO173429C (no) Anvendelse av ferromagnetiske partikler i kontrastmidler for NMR-avbildning
YU18799A (sh) Monociklični l-nukleozidi, njihovi analozi i njihova upotreba
ATE192339T1 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
DK0531421T3 (da) Kontrastmedier til ultralydsimagografi
ATE54568T1 (de) Kontrastmittel und deren verwendung.
AU7635396A (en) Treatment and diagnosis of infections due to helicobacter pylori
GR3002968T3 (en) Process for labelling substances with technetium or rhenium
NO964451L (no) Röntgenkontrastblandinger inneholdende farmasöytisk akseptable leirer
ATE393785T1 (de) Glykopeptide, deren herstellung und verwendung in der diagnose oder behandlung von multipler sklerose
NO971251D0 (no) Pröveenhet for engangsbruk, for undersökelse av kroppsvæske
DK197689D0 (da) Pyridazinderivater
IT1291278B1 (it) Preparazione farmaceutica a base di nimesulide per uso topico
AU8144894A (en) Biphenyl iodinated derivatives and their diagnostic use
AU5103096A (en) Use of ferrites for determining the perfusion of human tissue by m.r. diagnosis
ITMI912889A1 (it) Procedimento e apparecchiatura per l'abbinamento univoco di documenti radiografici, ecografici, tomografici, angiografici, di risonanza magnetico-nucleare e, in generale di tutti quei documenti che originano da procedimenti diagnostici che producono
RU95110928A (ru) Способ диагностики бактериемии (экспресс-посев крови)
DK535082A (da) Diaza-3,7a-cyclohepten(j,k)fluorener og fremgangsmaade til fremstilling deraf
SE9401596D0 (sv) New compounds
IT1214070B (it) Sistema medico rx diagnostico per rilevamento dei vari tipi di anomalie anatomiche uretro-vescicali
ITTO950546A0 (it) Metodo per la diagnosi di infezioni helycobacter pylori e relativo corredo diagnostico.
RU98114307A (ru) Способ лечения бактериального вагиноза
IT1260535B (it) Agente per lo studio della morfologia e della quantificazione del parenchima renale funzionante, composizioni che lo contengono e loro uso in medicina nucleare